{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:37:59Z","timestamp":1788907079042,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.htct.2023.05.006","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T15:47:36Z","timestamp":1688226456000},"page":"387-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Infections in patients with chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0077-4121","authenticated-orcid":false,"given":"Mariana","family":"Guarana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4867-0014","authenticated-orcid":false,"given":"Marcio","family":"Nucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.htct.2023.05.006_bib0001","series-title":"Neoplastic diseases of the blood","first-page":"1149","article-title":"Prevention of infections in patients with hematological malignancies","author":"Nucci","year":"2013"},{"issue":"10129","key":"10.1016\/j.htct.2023.05.006_bib0002","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.htct.2023.05.006_bib0003","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1600-0609.1992.tb01805.x","article-title":"Infections and serum IgG levels in patients with chronic lymphocytic leukemia","volume":"48","author":"Itala","year":"1992","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.htct.2023.05.006_bib0004","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","article-title":"Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy","volume":"15","author":"Burger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.htct.2023.05.006_bib0005","first-page":"98","article-title":"The infectious complications of chronic lymphocytic leukemia","volume":"25","author":"Morrison","year":"1998","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.htct.2023.05.006_bib0006","first-page":"374","article-title":"Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up","volume":"78","author":"Molica","year":"1993","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.htct.2023.05.006_bib0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","article-title":"Immune defects in patients with chronic lymphocytic leukemia","volume":"55","author":"Ravandi","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"10.1016\/j.htct.2023.05.006_bib0008","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.htct.2023.05.006_bib0009","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cncr.22094","article-title":"The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia","volume":"107","author":"Francis","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.htct.2023.05.006_bib0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1445-5994.1990.tb00370.x","article-title":"Complications and causes of death in B cell chronic lymphocytic leukaemia: a long term study of 105 patients","volume":"20","author":"Robertson","year":"1990","journal-title":"Aust N Z J Med"},{"issue":"4","key":"10.1016\/j.htct.2023.05.006_bib0011","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.htct.2023.05.006_bib0012","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","article-title":"Infections in patients with chronic lymphocytic leukemia treated with fludarabine","volume":"129","author":"Anaissie","year":"1998","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.htct.2023.05.006_bib0013","doi-asserted-by":"crossref","first-page":"466","DOI":"10.7326\/0003-4819-117-6-466","article-title":"Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone","volume":"117","author":"Anaissie","year":"1992","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.htct.2023.05.006_bib0014","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1080\/10428190412331283260","article-title":"Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"45","author":"Zhu","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.htct.2023.05.006_bib0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.htct.2023.05.006_bib0016","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.htct.2023.05.006_bib0017","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428190902730219","article-title":"Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis","volume":"50","author":"Aksoy","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1016\/j.htct.2023.05.006_bib0018","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials","volume":"103","author":"Vidal","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9747","key":"10.1016\/j.htct.2023.05.006_bib0019","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.htct.2023.05.006_bib0020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2023.05.006_bib0021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.htct.2023.05.006_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MOH.0b013e32834da987","article-title":"Neutropenia after rituximab treatment: new insights on a late complication","volume":"19","author":"Wolach","year":"2012","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.htct.2023.05.006_bib0023","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nri2729","article-title":"Effector and regulatory B cells: modulators of CD4+ T cell immunity","volume":"10","author":"Lund","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.htct.2023.05.006_bib0024","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.htct.2023.05.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122171","article-title":"Prophylaxis and Treatment of Pneumocystis jiroveci pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.htct.2023.05.006_bib0026","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2023.05.006_bib0027","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/asheducation-2014.1.576","article-title":"Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy","volume":"2014","author":"Kusumoto","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"13","key":"10.1016\/j.htct.2023.05.006_bib0028","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study","volume":"16","author":"van Oers","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.htct.2023.05.006_bib0029","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.htct.2023.05.006_bib0030","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9980","key":"10.1016\/j.htct.2023.05.006_bib0031","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.htct.2023.05.006_bib0032","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.2013.281115","article-title":"FDA: increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.htct.2023.05.006_bib0033","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system","volume":"15","author":"Raisch","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.htct.2023.05.006_bib0034","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2023.05.006_bib0035","article-title":"Alemtuzumab for patients with chronic lymphocytic leukaemia","author":"Skoetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.htct.2023.05.006_bib0036","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1086\/375690","article-title":"Tuberculosis due to Mycobacterium bovis after alemtuzumab administration","volume":"37","author":"Abad","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.htct.2023.05.006_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"25","key":"10.1016\/j.htct.2023.05.006_bib0038","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.htct.2023.05.006_bib0039","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.htct.2023.05.006_bib0040","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.htct.2023.05.006_bib0041","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid malignancies","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.htct.2023.05.006_bib0042","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.htct.2023.05.006_bib0043","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.htct.2023.05.006_bib0044","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2018-02-832154","article-title":"Ibrutinib and fungus: an invasive concern","volume":"131","author":"Rogers","year":"2018","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.htct.2023.05.006_bib0045","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10232","key":"10.1016\/j.htct.2023.05.006_bib0046","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.htct.2023.05.006_bib0047","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.htct.2023.05.006_bib0048","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.htct.2023.05.006_bib0049","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.htct.2023.05.006_bib0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.htct.2023.05.006_bib0051","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.htct.2023.05.006_bib0052","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study","volume":"13","author":"Garcia-Suarez","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.htct.2023.05.006_bib0053","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41375-021-01450-8","article-title":"COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study","volume":"35","author":"Chatzikonstantinou","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.htct.2023.05.006_bib0054","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.1002\/ajh.26459","article-title":"COVID-19 vaccine response in patients with hematologic malignancy: a systematic review and meta-analysis","volume":"97","author":"Gong","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.htct.2023.05.006_bib0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"Benjamini","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.htct.2023.05.006_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100931","article-title":"COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: a clarion call for maintaining mitigation and ramping-up research","volume":"54","author":"Wang","year":"2022","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.htct.2023.05.006_bib0057","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.2021014124","article-title":"COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA","volume":"139","author":"Pagano","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.htct.2023.05.006_bib0058","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.htct.2023.05.006_bib0059","unstructured":"Morrison V.A. Prevention of infections in patients with chronic lymphocytic leukemia. In: Bow E (ed), UpToDate, Waltham, MA, 2022 (Accessed on August 10, 2022)."},{"issue":"1","key":"10.1016\/j.htct.2023.05.006_bib0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.htct.2023.05.006_bib0061","unstructured":"Nucci M, Anaissie E. Infections in patients with multiple myeloma. In: Bow E (ed), UpToDate, Waltham, MA, 2023 (Accessed on February 15, 2023)."}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137923001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137923001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:36:47Z","timestamp":1762868207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137923001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2531137923001086"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2023.05.006","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections in patients with chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2023.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}